Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer

Lung Cancer

Volumn 43, Issue 2, 2004, Pages 223-240

  Laurie, Scott A ^a   Logan, Diane ^b   Markman, Barbara R ^c   Mackay, Jean A ^c   Evans, William K ^d   Alam, Yasmin ^e   Brundage, Michael ^e   Dar, A R ^e   Campling, Barbara ^e   Darling, Gail ^e   Dixon, Peter ^e   Ellis, Peter ^e   Falkson, Conrad ^e   Feld, Ronald ^e   Findlay, Brian ^e   Goss, Glen ^e   Graham, Ian ^e   Gregg, Richard ^e   Iscoe, Neill ^e   Kocha, Walter ^e   Kolin, Arnost ^e   Kotalik, Jaro ^e   Lochrin, Catherine ^e   Lopez, Pedro ^e   Malthaner, Richard ^e   Maziak, Donna ^e   McIvor, Andrew ^e   Meng, Joanne ^e   Miller, John ^e   Noble, Jonathan ^e   Okawara, Gordon ^e   Rusthoven, James ^e   Shepherd, Frances ^e   Stewart, David ^e   Ung, Yee Chung ^e   Urschel, John ^e   Vincent, Mark ^e   Wenckebach, Georg ^e   Yue, Edward ^e   Gagliardi, Anna ^e   Baig, Lubna ^e   Newman, Toni ^e   more..

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CANCER CARE ONTARIO   (Canada)

^e NONE

Author keywords

Antineoplastic agents; Carcinoma; Drug therapy; Practice guidelines; Small cell lung

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOFOS; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PLATINUM; TENIPOSIDE; VINCRISTINE; VINDESINE;

ALOPECIA; ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER PROGRAM; CONVALESCENCE; ESOPHAGITIS; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFORMATION PROCESSING; LEUKOPENIA; LITERATURE; LUNG SMALL CELL CANCER; LUNG TOXICITY; MEDICAL SPECIALIST; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 9144222573     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.09.002     Document Type: Article

References (65)

1. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J. Clin. Oncol. 10:1992;890-895.
2. Pignon J.P., Arriagada R., Ihde D.C.et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327:1992;1618-1624.
3. Okawara G, Gagliardi A, Evans WK and the Cancer Care Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group. The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer. Curr Oncol 2000;7:162-172.
4. Kotalik J, Yu E, Markman BR, et al. and the Cancer Care Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group. Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;50:309-316.
5. Browman G.P., Levine M.N., Mohide E.A.et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J. Clin. Oncol. 13:1995;502-512.
6. Review Manager (RevMan) [computer program]. Version 4.1 for Windows. Oxford, England, The Cochrane Collaboration, 2000.
7. Jackson D.V., Case L.D. Small-cell lung cancer: a 10-year perspective. Semin. Oncol. 13(3 suppl 3):1986;63-74.
8. Messeih A.A., Schweitzer J.M., Lipton A.et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat. Rep. 71:1987;61-66.
9. Jett J.R., Everson L., Therneau T.M.et al. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J. Clin. Oncol. 8:1990;33-39.
10. Nikkanen V, Liippo K, Ojala A, et al. Vincristine doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer. Acta Oncologica 1990;29:421-424.
11. Bunn P.A. Jr., Greco F.A., Einhorn L. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin. Oncol. 13(3 suppl 3):1986;45-53.
12. Hong W.K., Nicaise C., Lawson R.et al. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J. Clin. Oncol. 7:1989;450-456.
13. Erkisi M., Unsal M., Tunali C.et al. A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer. J. Chemother. 5:1993;56-59.
14. Abratt R.P., Salton D.G.M., Malan J.R.et al. A prospective randomised study in limited disease small cell carcinoma - doxorubicin and vincristine plus either cyclophosphamide or etoposide. Eur. J. Cancer. 31A:1995;1637-1639.
15. Wolf M., Havemann K., Holle R.et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J. Clin. Oncol. 5:1987;1880-1889.
16. Miyamoto H., Nakabayashi T., Isobe H.et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology. 49:1992;431-435.
17. Gómez-Codina J., Artal A., González-Larriba J.L.et al. Randomized trial of high-dose epirubicin-cisplatin versus etoposide-cisplatin in small-cell lung cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 18:1999;469a. [Abstract 1810].
18. Mavroudis D., Papadakis E., Veslemes M.et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann. Oncol. 12:2001;463-470.
19. Niiranen A., Holsti L.R., Salmo M.et al. Vincristine-cyclophosphamide, the classical two-drug regimen for small-cell lung cancer, evaluated in a randomized study with vindesine. Am. J. Clin. Oncol. 10:1987;507-511.
20. Sculier J.P., Klastersky J., Libert P.et al. A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. Ann. Oncol. 1:1990;128-133.
21. Havemann K. Alternating chemotherapy with Adriamycin/ifosfamide/ vincristin (AIO) and either Cisplatin/Etoposide or Carboplatin/Etoposide in small cell lung cancer (SCLC) [abstract]. Eur. J. Cancer. 27(Suppl 2):1991;S349. [Abstract 2142].
22. Joss R.A., Alberto P., Bleher E.A.et al. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Ann. Oncol. 5:1994;921-928.
23. Tummarello D., Mari D., Graziano F.et al. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-α maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Cancer. 80:1997;2222-2229.
24. Fukuoka M., Furuse K., Saijo N.et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J. Natl. Cancer Inst. 83:1991;855-861.
25. Joos G., Pinson P., Van Renterghem D.et al. A randomized study comparing vincristine, adriamycin, cyclophosphamide (VAC) to carboplatin, etoposide (CE) in previously untreated small cell lung cancer (SCLC) [abstract]. Proc. Am. Soc. Clin. Oncol. 18:1999;470a. [Abstract 1812].
26. Sundstrom S., Bremnes R.M., Kaasa S.et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J. Clin. Oncol. 20:2002;4665-4672.
27. Johnson D.H., Bass D., Einhorn L.H.et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 11:1993;1223-1229.
28. Goodman G.E., Crowley J.J., Blasko J.C.et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group study. J. Clin. Oncol. 8:1990;39-47.
29. Tonato M., Crino L., Meacci M.L.et al. Long term results in small cell lung cancer. Analysis of ten years' experience in Umbria. Cancer Ther. Control. 2:1991;81-89.
30. Feld R., Evans W.K., Coy P.et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J. Clin. Oncol. 5:1987;1401-1409.
31. Wolf M., Pritsch M., Drings P.et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. J. Clin. Oncol. 9:1991;614-624.
32. Ueoka H., Kiura K., Tabata M.et al. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/ cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma. Results of long term follow-up. Cancer. 83:1998;283-290.
33. Abratt R.P., Willcox P.A., de Groot M.et al. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur. J. Cancer. 27:1991;28-30.
34. Johnson D.H., Ruckdeschel J.C., Keller J.H.et al. A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer. 67(suppl 1):1991;245-249.
35. Maksymiuk A.W., Jett J.R., Earle J.D.et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial. J. Clin. Oncol. 12:1994;70-76.
36. Greco F.A., Hainsworth J.D. Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: randomized phase II trial. Lung Cancer. 12(Suppl 3):1995;S85-S95.
37. Figueredo A.T., Hryniuk W.M., Strautmanis I.et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J. Clin. Oncol. 3:1985;54-64.
38. Arriagada R., Le Chevalier T., Pignon J.P.et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med. 329:1993;1848-1852.
39. Kolaric K., Oreskovic B., Vukas D.et al. Standard vs. high-dose epirubicin in combination chemotherapy of small cell lung cancer (SCLC) - results of a phase III randomized trial. Libri. Oncol. 23:1994;177-185.
40. Le Chevalier T, Riviere A, Pignon JP, et al. Is there an optimal dose for frontline chemotherapy (CT) in limited small cell lung cancer (SCLC)? Results of a randomized trial in 295 patients from the French Cancer Centers Group [abstract]. Proc Am Soc Clin Oncol 2002;21 [Abstract 1172].
41. Wolf M., Hans K., Drings P.et al. Treatment intensification with GM-CSF in patients with non-metastatic small cell lung cancer (NMSCLC). Results of a multicenter trial including 330 patients abstract. Proc. Am. Soc. Clin. Oncol. 15:1996;270. [Abstract 716].
42. Steward W.P., von Pawel J., Gatzemeier U.et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J. Clin. Oncol. 16:1998;642-650.
43. Masutani M., Ochi Y., Kadota A.et al. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Oncol. Rep. 7:2000;305-310.
44. Thatcher N., Girling D.J., Hopwood P.et al. for the Medical Research Council Lung Cancer Working Party. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. J. Clin. Oncol. 18:2000;395-404.
45. Ardizzoni A., Tjan-Heijnen V.C.G., Postmus P.E.et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer - Lung Cancer Group phase III trial - 08923. J. Clin. Oncol. 20:2002;3947-3955.
46. Sculier J.P., Paesmans M., Bureau G.et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J. Clin. Oncol. 11:1993;1858-1865.
47. Souhami R.L., Rudd R., Ruiz de Elivira M.C.et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J. Clin. Oncol. 12:1994;1806-1813.
48. Urban T., Chastang C., Lebas F.X.et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma. Cancer. 86:1999;2238-2245.
49. Hirsch F.R., Osterlind K., Jeppesen N.et al. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. Ann. Oncol. 12:2001;647-653.
50. Humblet Y., Symann M., Bosly A.et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J. Clin. Oncol. 5:1987;1864-1873.
51. Cullen M., Morgan D., Gregory W.et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother. Pharmacol. 17:1986;157-160.
52. Bleehen N.M., Fayers P.M., Girling D.J.et al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br. J. Cancer. 59:1989;584-590.
53. Byrne M.J., van Hazel G., Trotter J.et al. Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. Br. J. Cancer. 60:1989;413-418.
54. Giaccone G., Dalesio O., McVie G.J.et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J. Clin. Oncol. 11:1993;1230-1240.
55. Spiro S.G., Souhami R.L., Geddes D.M.et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br. J. Cancer. 59:1989;578-583.
56. Veslemes M., Polyzos A., Latsi P.et al. Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide. J. Chemother. 10:1998;136-140.
57. Pujol J.L., Carestia L., Daurès J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br. J. Cancer. 83:2000;8-15.
58. Mascaux C., Paesmans M., Berghmans T.et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 30:2000;23-36.
59. Ihde D, Pass H, Glatstein E. Small cell lung cancer. In: DeVita V, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippencott/Raven Publishers; 1997. p. 911-49.
60. Turrisi A.T., Sherman C.A. The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur. J. Cancer. 38:2002;279-291.
61. Shepherd F.A. The role of chemotherapy in the treatment of small cell lung cancer. Chest Surg. Clin. North Am. 7:1997;113-133.
62. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63:1979;1727-1733.
63. Goldie J.H., Coldman A.J., Gudauskas G.A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 66:1982;439-449.
64. Schabel F.M. Jr., Trader M.W., Laster W.R. Jr.et al. cis- Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumours of mice. Cancer Treat. Rep. 63:1979;1459-1473.
65. Skarlos D.V., Samantas E., Kosmidis P.et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann. Oncol. 5:1994;601-607.